

November 03, 2023

The Manager  
BSE Limited(SME),  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400 001

Dear Sir,

**Scrip No. 543363**  
**BSE Symbol: PREVEST**

Sub: **Outcome of the Board Meeting held today i.e., November 03, 2023**

With reference to the captioned subject and in compliance with the regulation 30 and 33 and other applicable regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., Friday, November 03, 2023 (commenced at 04:00 p.m. and concluded at 05.05 p.m.), inter-alia have the following:

1. Considered and approved the un-audited financial results (Standalone and Consolidated) of the Company for the quarter and half year ended on September 30, 2023.
2. Considered and approved the Limited Review Report of the Auditors, in respect of the un-audited financial results of the Company for the quarter and half year ended on September 30, 2023.

A copy of the un-audited Financial Results adopted and approved by the Board of Directors for the quarter ended on September 30, 2023, and limited review report of the Auditors thereon is attached herewith for your perusal.

Please take the same on your records and suitably disseminated at all concerned.

Thanking You,  
Yours faithfully,

**For Prevest Denpro Limited**

AMAN  
SADHOTRA

Digitally signed by  
AMAN SADHOTRA  
Date: 2023.11.03  
17:12:37 +05'30'

**Aman Sadhotra**  
**Company Secretary and Compliance Office**  
**M. No- 66562**

STATEMENT OF STANDALONE ASSETS AND LIABILITIES

Rs In Lakh

		As at September 30, 2023	As at March 31, 2023
<b>I.</b>	<b><u>EQUITY &amp; LIABILITIES</u></b>		
<b>1</b>	<b>Shareholders Funds</b>		
	Share Capital	1,200.30	1,200.30
	Reserves & Surplus	6,830.25	6,079.44
<b>2</b>	<b>Share Application Money Pending Allotments</b>	-	-
		<b>8,030.55</b>	<b>7,279.74</b>
<b>3</b>	<b>Non- current Liabilities</b>		
	Long- Term Borrowings	-	-
	Deferred Tax Liabilities (Net)	47.45	37.12
		<b>47.45</b>	<b>37.12</b>
<b>4</b>	<b>Current Liabilities</b>		
	Trade Payables		
	1. total outstanding dues of micro enterprises and small enterprises	59.87	41.52
	2. total outstanding dues of trade payables other than micro and small enterprises	103.80	98.27
	Other Current Liabilities	333.17	404.25
	Short- Term Provisions	19.35	-
		<b>516.19</b>	<b>544.04</b>
	<b>Total Equity &amp; Liabilities</b>	<b>8,594.19</b>	<b>7,860.90</b>
<b>1</b>	<b>Non- Current Assets</b>		
	<b><u>Property, Plant &amp; Equipment and Intangible Assets</u></b>		
	Property, Plant & Equipment	1,520.61	740.59
	Capital Works in progress	1,122.09	1,688.72
		<b>2,642.70</b>	<b>2,429.31</b>
	Non-Current Investments	5.00	-
		<b>5.00</b>	<b>-</b>
<b>2</b>	<b>Current Assets</b>		
	Current Investment	142.90	119.40
	Inventories	650.30	478.89
	Trade receivables	776.98	430.47
	Cash & cash equivalents	3,946.45	3,900.31
	Short- Term Loans & Advances	134.36	174.16
	Other Current Assets	295.50	328.37
		<b>5,946.49</b>	<b>5,431.59</b>
	<b>Total Assets</b>	<b>8,594.19</b>	<b>7,860.90</b>

For Prevest Denpro Limited

  
Atul Modi  
(Managing Director)  
DIN-00788272



**Statement of unaudited Standalone Financials Results for the Quarter and Half year ended on 30th September 2023**

Rs in Lakh

PARTICULARS	Quarter Ended			Six Month Ended		Year Ended
	30/09/2023	30/06/2023	30/09/2022	30/09/2023	30/09/2022	31/03/2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1 Income From Operation</b>						
(a) Net Sales / Income from Operation (Net of Taxes)	1,317.78	1,339.40	1,144.72	2,657.17	2,381.33	4,985.41
(b) Other Income	73.72	60.52	58.12	134.24	119.90	203.35
<b>Total Revenue</b>	<b>1,391.50</b>	<b>1,399.92</b>	<b>1,202.84</b>	<b>2,791.41</b>	<b>2,501.22</b>	<b>5,188.76</b>
<b>2 Expenses</b>						
(a) Cost of Material Consumed	351.01	352.84	306.26	703.84	676.29	1,276.08
(b) Purchase of Stock-in- Trade	-	-	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5.09)	(9.21)	(4.69)	(14.30)	(9.04)	(15.29)
(d) Finance Cost	-	-	-	-	-	-
(d) Employee benefit expenses	230.71	239.60	196.11	470.32	383.66	819.07
(e) Depreciation and amortization expenses	21.95	17.49	18.88	39.44	33.52	67.51
(f) Other Expenses	290.49	259.57	201.83	550.06	427.53	945.71
<b>Total Expenses</b>	<b>889.07</b>	<b>860.30</b>	<b>718.39</b>	<b>1,749.37</b>	<b>1,511.97</b>	<b>3,093.09</b>
<b>3 Profit/(Loss) from before exceptional and extraordinary items (1-2)</b>	<b>502.43</b>	<b>539.62</b>	<b>484.45</b>	<b>1,042.05</b>	<b>989.25</b>	<b>2,095.68</b>
<b>Profit/(Loss) from ordinary activities, before finance cost and exceptional items (3+4)</b>	<b>502.43</b>	<b>539.62</b>	<b>484.45</b>	<b>1,042.05</b>	<b>989.25</b>	<b>2,095.68</b>
Financial Cost	-	-	-	-	-	-
<b>Profit/(Loss) from ordinary activities, after finance cost but before exceptional items (5-6)</b>	<b>502.43</b>	<b>539.62</b>	<b>484.45</b>	<b>1,042.05</b>	<b>989.25</b>	<b>2,095.68</b>
4 Exceptional Item	-	-	-	-	-	-
<b>5 Profit/(Loss) from ordinary activities before tax (3+4)</b>	<b>502.43</b>	<b>539.62</b>	<b>484.45</b>	<b>1,042.05</b>	<b>989.25</b>	<b>2,095.68</b>
6 Tax Expenses						
Current Tax	113.84	135.39	140.23	249.23	285.87	516.16
Earliyer Year Tax	-	-	-1.46	-	(1.46)	0.27
Deffered Tax	14.55	-4.22	12.47	10.33	3.45	8.24
<b>7 Net Profit/(Loss) from Ordinary activity after tax (5-6)</b>	<b>374.04</b>	<b>408.45</b>	<b>333.21</b>	<b>782.49</b>	<b>701.40</b>	<b>1,571.01</b>
8 Extraordinary Item (net of tax Rs expenses)	-	-	-	-	-	-
<b>9 Net profit/(loss) for the period (7+8)</b>	<b>374.04</b>	<b>408.45</b>	<b>333.21</b>	<b>782.49</b>	<b>701.40</b>	<b>1,571.01</b>
<b>Details of Share Capital</b>						
10 Paid up Equity Share Capital-Face Value Rs 10/- each	120.00	120.00	120.00	120.00	120.00	120.00
11 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year.	-	-	-	-	-	6,079.44
12 Earnings per Share (EPS) , in Rs (not annualised) ( Equity Share of face value of Rs 10/- each)						
(a) Basic	3.12	3.40	2.78	6.52	5.84	13.09
(b) Diluted	3.12	3.40	2.78	6.52	5.84	13.09

## Notes:-

- The above financial results were reviewed and recommended by the Audit Committee of the company and, the same were approved by the Board of Director of the company at their respective meeting held on 03/11/2023
- The Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- The above Financial Statements have been prepared in accordance with applicable Accounting Standards issued by the Institute of Chartered Accountants of India
- The figures for the previous period have been restated / regrouped / reclassified, wherever necessary, in order to make them comparable.

For Prevest Denpro Limited

  
**Atul Modi**  
 (Managing Director)  
 DIN-00788272



**CASH FLOW-STATEMENT**

Rs. In Lakhs

Particulars	For the Half-year ended Sept 30, 2023	Year Ended 31.03.2023 Audited
<b>Cash Flow From Operating Activities:</b>		
Net Profit before tax as per Profit And Loss A/c	1,042.05	2,095.68
<b>Adjustments for:</b>		
Depreciation & Amortisation Expense	39.44	67.51
Interest Income	(117.15)	(161.55)
<b>Operating Profit Before Working Capital Changes</b>	<b>964.34</b>	<b>2,001.64</b>
Adjusted for (Increase)/ Decrease in:		
Short term provision	-	(9.88)
Trade Receivables	(346.52)	(198.37)
Inventories	(171.41)	(152.52)
Other current assets	72.67	(95.64)
Trade Payables	23.88	(23.94)
Other Current Liabilities	(71.08)	37.93
<b>Cash Generated From Operations</b>	<b>(492.46)</b>	<b>(442.43)</b>
Appropriation of Profit		
Net Income Tax paid/ refunded	229.87	516.44
<b>Net Cash Flow from/(used in) Operating Activities: (A)</b>	<b>242.00</b>	<b>1,042.77</b>
<b>Cash Flow From Investing Activities:</b>		
Net (Purchases)/Sales of Fixed Assets (including capital work in progress)	-252.84	(1,352.77)
Interest Income	117.15	161.55
Net Increase/(Decrease) in Current Investment	(28.50)	(46.50)
<b>Net Cash Flow from/(used in) Investing Activities: (B)</b>	<b>(164.19)</b>	<b>(1,237.72)</b>
<b>Cash Flow from Financing Activities:</b>		
Net Increase/(Decrease) in Long Term Borrowings	-	(136.67)
Dividend paid	(31.68)	-
<b>Net Cash Flow from/(used in) Financing Activities (C)</b>	<b>(31.68)</b>	<b>(136.67)</b>
Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	<b>46.13</b>	<b>(331.62)</b>
Cash & Cash Equivalents As At Beginning of the Year	<b>3,900.31</b>	<b>4,231.93</b>
Cash & Cash Equivalents As At End of the Year	<b>3,946.45</b>	<b>3,900.31</b>

For Prevest Denpro Limited

  
**Atul Modi**  
 (Managing Director)  
 DIN-00788272

**Limited Review Report on Unaudited Financial Results of Prevest Denpro Limited for the quarter and Half Year ended 30<sup>th</sup> September 2023 pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

To

The Board of Directors


Prevest Denpro Limited

We have reviewed the accompanying statement of unaudited financial results of Prevest Denpro Limited for the quarter and six month ended 30<sup>th</sup> September 2023, ("the Statement"). This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mittal & Associates.,  
Chartered Accountants  
FRN: 106456W

  
Hemant Bohra  
Partner


Membership No 165667  
UDIN: - 23165667BGTIKL4607  
Date: 3<sup>rd</sup> November 2023  
Place: Mumbai



**STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES**
**Rs In Lakh**

Particulars		As at September 30, 2023
<b>1.</b>	<b><u>EQUITY &amp; LIABILITIES</u></b>	
<b>1</b>	<b>Shareholders Funds</b>	
	Share Capital	1,200.30
	Reserves & Surplus	6,820.50
<b>2</b>	<b>Share Application Money Pending Allotments</b>	-
		<b>8,020.80</b>
<b>3</b>	<b>Non- current Liabilities</b>	
	Long- Term Borrowings	-
	Deferred Tax Liabilities (Net)	47.45
		<b>47.45</b>
<b>4</b>	<b>Current Liabilities</b>	
	Trade Payables	
	1. total outstanding dues of micro enterprises and small enterprises	59.87
	2. total outstanding dues of trade payables other than micro and small enterprises	103.87
	Other Current Liabilities	336.86
	Short- Term Provisions	19.35
		<b>519.95</b>
	<b>Total Equity &amp; Liabilities</b>	<b>8,588.21</b>
<b>1</b>	<b>Non- Current Assets</b>	
	<b><u>Property, Plant &amp; Equipment and Intangible Assets</u></b>	
	Property, Plant & Equipment	1,520.61
	Capital Works in progress	1,122.09
		<b>2,642.70</b>
	Non-Current Investments	-
		-
<b>2</b>	<b>Current Assets</b>	
	Current Investment	142.90
	Inventories	650.54
	Trade receivables	776.72
	Cash & cash equivalents	3,950.15
	Short- Term Loans & Advances	129.21
	Other Current Assets	295.99
		<b>5,945.51</b>
	<b>Total Assets</b>	<b>8,588.21</b>

For Prevest Denpro Limited

  
 Atul Modi

(Managing Director)

DIN-00788272



Statement of unaudited Consolidated Financials Results for the Quarter and Half year ended on 30th September 2023				
	PARTICULARS	Quarter Ended		Six Month Ended
		30/09/2023	30/06/2023	30/09/2023
		Unaudited	Unaudited	Unaudited
1	<b>Income From Operation</b>			
	(a) Net Sales / Income from Operation (Net of Taxes)	1,317.54	1,339.40	2,656.93
	(b) Other Income	73.72	60.52	134.24
	<b>Total Revenue</b>	<b>1,391.26</b>	<b>1,399.92</b>	<b>2,791.17</b>
2	<b>Expenses</b>			
	(a) Cost of Material Consumed	351.01	352.84	703.84
	(b) Purchase of Stock-in- Trade	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5.33)	(9.21)	(14.54)
	(d) Finance Cost	-	-	-
	(d) Employee benefit expenses	238.72	239.60	478.32
	(e) Depreciation and amortization expenses	21.95	17.49	39.44
	(f) Other Expenses	292.24	259.57	551.81
	<b>Total Expenses</b>	<b>898.58</b>	<b>860.30</b>	<b>1,758.88</b>
3	<b>Profit/(Loss) from before exceptional and extraordinary items (1-2)</b>	<b>492.68</b>	<b>539.62</b>	<b>1,032.30</b>
	<b>Profit/(Loss) from ordinary activities, before finance cost and exceptional items (3+4)</b>	<b>492.68</b>	<b>539.62</b>	<b>1,032.30</b>
	Financial Cost			
	<b>Profit/(Loss) from ordinary activities, after finance cost but before exceptional items (5-6)</b>	<b>492.68</b>	<b>539.62</b>	<b>1,032.30</b>
4	Exceptional Item			
5	<b>Profit/(Loss) from ordinary activities before tax (3+4)</b>	<b>492.68</b>	<b>539.62</b>	<b>1,032.30</b>
6	<b>Tax Expenses</b>			
	Current Tax	113.84	135.39	249.23
	Earliyer Year Tax	-	-	-
	Deffered Tax	14.55	-4.22	10.33
7	<b>Net Profit/(Loss) from Ordinary activity after tax (5-6)</b>	<b>364.29</b>	<b>408.45</b>	<b>772.74</b>
8	Extraordinary Item (net of tax Rs expenses)			
9	<b>Net profit/(loss) for the period (7+8)</b>	<b>364.29</b>	<b>408.45</b>	<b>772.74</b>
	<b>Details of Share Capital</b>			
10	Paid up Equity Share Capital-Face Value Rs 10/- each	120.00	120.00	120.00
11	Reserve excluding, Revaluation Reserves as per balance sheet of previous accounting year.			
11	<b>Earnings per Share (EPS) , in Rs (not annualised)</b> ( Equity Share of face value of Rs 10/- each)			
	(a) Basic	3.04	3.40	6.44
	(b) Diluted	3.04	3.40	6.44

Notes:-

- The above Consolidated financial results were reviewed and recommended by the Audit Committee of the company and, the same were approved by the Board of Director of the company at their respective meeting held on 03/11/2023
- This consolidated financial result includes, results of Densio Biomed Limited (Wholly Owned Subsidiary of Prevest Denpro Limited)
- As the company has prepared consolidated financial results for the first time in June 2023 so comparative figures of quarter and half year ended September 2022 is not provided.
- The Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- The above Consolidated Financial Statements have been prepared in accordance with applicable Accounting Standards issued by the Institute of Chartered Accountants of India

For Prevest Denpro Limited

  
  
**Atul Modi**  
 (Managing Director)  
 DIN-00788272

CONSOLIDATED CASH FLOW-STATEMENT

Rs. In Lakhs

Particulars	For the Half-year ended Sept 30, 2023 Un-audited
<b>Cash Flow From Operating Activities:</b>	
Net Profit before tax as per Profit And Loss A/c	1,032.30
<b>Adjustments for:</b>	
Depreciation & Amortisation Expense	39.44
Interest Income	(117.15)
<b>Operating Profit Before Working Capital Changes</b>	<b>954.59</b>
Adjusted for (Increase)/ Decrease in:	
Short term provision	-
Trade Receivables	(346.26)
Inventories	(171.65)
Other current assets & Short-term loans & Advances	77.33
Trade Payables	23.95
Other Current Liabilities	(67.39)
<b>Cash Generated From Operations</b>	<b>(484.01)</b>
Appropriation of Profit	
Net Income Tax paid/ refunded	229.87
<b>Net Cash Flow from/(used in) Operating Activities: (A)</b>	<b>240.71</b>
<b>Cash Flow From Investing Activities:</b>	
Net (Purchases)/Sales of Fixed Assets (including capital work in progress)	-252.84
Interest Income	117.15
Net Increase/(Decrease) in Current Investment	(23.50)
<b>Net Cash Flow from/(used in) Investing Activities: (B)</b>	<b>(159.19)</b>
<b>Cash Flow from Financing Activities:</b>	
Net Increase/(Decrease) in Long Term Borrowings	-
Dividend paid	(31.68)
<b>Net Cash Flow from/(used in) Financing Activities (C)</b>	<b>(31.68)</b>
Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	<b>49.84</b>
Cash & Cash Equivalents As At Beginning of the Year	<b>3,900.31</b>
Cash & Cash Equivalents As At End of the Year	<b>3,950.15</b>

For Prevest Denpro Limited

  
**Atul Modi**  
**(Managing Director)**  
DIN-00788272





**Limited Review Report on Unaudited Consolidated Financial Results of Prevest Denpro Limited for the quarter and Half Year ended 30<sup>th</sup> September 2023 pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

To

The Board of Directors

Prevest Denpro Limited

We have reviewed the accompanying statement of unaudited consolidated financial results of Prevest Denpro Limited ("the Parent") and its subsidiary (the parent and its subsidiary together referred to as "the group") for the quarter and six months ended 30<sup>th</sup> September 2023, ("the Statement").

This statement is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statement includes the results of the following entities:

Holding/parent Company: - Prevest Denpro Limited  
Subsidiary Company: - Denvisio Biomed Limited

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mittal & Associates.,  
Chartered Accountants  
FRN: 106456W

  
Hemant Bohra

Partner

Membership No 165667

UDIN: - 23165667BGTIKM1696

Date: 3<sup>rd</sup> November 2023

Place: Mumbai

